Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists to watch depression treatment reshape the brain in real time

NCT ID NCT07620288

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will use advanced brain scans to see how a quick, 3-minute form of magnetic brain stimulation changes the brain in people with major depression. Twenty adults will receive one week of treatment and have PET and MRI scans before and after. The goal is to understand the brain mechanisms behind the treatment, not to test if it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive Transcranial Magnetic Stimulation (rTMS) - specifically intermittent Theta Burst Stimulation (iTBS)
What this could lead to
If successful, this study could reveal exactly how this brain stimulation treatment changes the brain, helping to develop faster and more effective depression therapies.
What could go wrong
This is a very small, early-stage study (20 people) with no control group, so results may not apply to everyone. It is designed to understand brain changes, not to prove the treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria For inclusion in the study, participants must fulfill all the following criteria: 1. 18 to 55 years old. 2. Competent to provide voluntary informed consent. 3. English comprehension and verbal communication (participants must be able to both understand and speak English sufficiently to follow study procedures and be understood by study personnel 4. Referred by their treating physician. 5. Mini-International Neuropsychiatric Interview-confirmed diagnosis of MDD, as a single or recurring episode. 6. Symptoms of MDD have not improved after ≥ 1 adequate antidepressant medication trial in the current depressive episode29. 7. Baseline score of ≥18 on the 17-item Hamilton Rating Scale for Depression (HRSD-17). 8. Maintained a stable treatment regimen for at least four weeks prior to entering the study, defined as being on a stable antidepressant regimen, a stable psychotherapy regimen, both, or neither (i.e., no treatment), with no changes during this period. Exclusion Criteria Participants fulfilling any of the following criteria will be excluded from the study: 1. Any comorbid mental health disorders (including, but not limited to lifetime history of psychotic disorders, OCD, and/or bipolar I or II disorder) with the exception of anxiety/panic disorders, posttraumatic stress disorder and ADHD 2. Current or past (\< 3 months) substance (including nicotine) or alcohol abuse/dependence, as defined in DSM-5 criteria. 3. Positive urine test for illegal substances, cannabis, or cotinine. 4. Significant unstable medical or neurologic illness confirmed by medical history (e.g. uncontrolled diabetes, or renal dysfunction). 5. Breastfeeding or pregnant (confirmed via urine test). 6. BMI \> 30 or BMI \< 18. 7. Contraindication for TMS (e.g., personal history of epilepsy or convulsion, metallic head implant, pacemaker). 8. Contraindication for MRI (e.g. metallic implant, claustrophobia). 9. Have received a cumulative radioactivity dose \> 15.2mSv during the last 12 months. 10. Have active malignancies (due to high chance of undergoing radiation therapy). 11. Suicide attempt in the past three months and/or active suicidal intent. 12. Failed (non-response) course of ECT or rTMS treatment in the current depressive episode. 13. Benzodiazepine or lithium use. Other psychotropic medications (e.g. ADHD medications) are permitted, if stable in the 4 weeks prior to and during the treatment course) 14. Any other condition that, in the opinion of the investigators, would adversely affect the participant's ability to complete the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Royal's Institute of Mental Health Research

    Ottawa, Ontario, K1Z 7K4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.